Literature DB >> 27121187

The Importance of Melatonin and Mitochondria Interaction in Mood Disorders and Schizophrenia: A Current Assessment.

Abdülhadi Cihangir Uguz1, Kadir Demirci, Javier Espino.   

Abstract

Mitochondria play a critical role in regulating cellular functions, such as redox signaling, calcium homeostasis, and apoptosis. Also, mitochondria are crucial for neurogenesis and neuronal functions. Melatonin is an indole analog hormone, which is generally produced by the pineal gland. It plays a vital role in circadian rhythm and act as a powerful antioxidant by scavenging free radicals, immunomodulators, and anticancer agents. Schizophrenia and mood disorders are the two major psychiatric disorders. Disturbances of sleep and circadian rhythms are well-known symptoms of schizophrenia and mood disorders (bipolar disorder, major depression). Since melatonin has a regulator effect on circadian rhythm and sleep quality, it has a close interaction with schizophrenia and mood disorders. Herein, we aimed to summarize the effects of melatonin on mitochondrial activity in schizophrenia and mood disorders.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27121187     DOI: 10.2174/0929867323666160428105849

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  3 in total

Review 1.  Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells.

Authors:  Samuel K Powell; Callan P O'Shea; Sara Rose Shannon; Schahram Akbarian; Kristen J Brennand
Journal:  Adv Neurobiol       Date:  2020

2.  Melatonin Mediates Protective Effects against Kainic Acid-Induced Neuronal Death through Safeguarding ER Stress and Mitochondrial Disturbance.

Authors:  Feixiao Xue; Cai Shi; Qingjie Chen; Weijian Hang; Liangtao Xia; Yue Wu; Sophia Z Tao; Jie Zhou; Anbing Shi; Juan Chen
Journal:  Front Mol Neurosci       Date:  2017-02-28       Impact factor: 5.639

Review 3.  The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment.

Authors:  Anna Giménez-Palomo; Seetal Dodd; Gerard Anmella; Andre F Carvalho; Giselli Scaini; Joao Quevedo; Isabella Pacchiarotti; Eduard Vieta; Michael Berk
Journal:  Front Psychiatry       Date:  2021-07-06       Impact factor: 4.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.